Home›Stock Screener›Dr. Agrawals Eye Hospital

Dr. Agrawals Eye Hospital Share Price Today | Stock Price & Dr. Agrawals Eye Hospital Share Screener

DRAGARWQ Healthcare Services
Live Share Price NSE
₹5995.50
▼ -92.00 (-1.51%)
2026-11-16 00:00:00
Live Share Price BSE
₹6010.30
▼ -87.30 (-1.43%)
2026-11-16 00:00:00

As of November 16, 2026, the live Dr. Agrawals Eye Hospital share price (NSE: DRAGARWQ) is ₹5,995.50 on NSE and ₹6,010.30 on BSE, down 1.51% from the previous close, with shares trading between ₹5,961.00 and ₹6,187.00 in today's trading session, and a 52-week range of ₹4,787.85–₹6,087.50. Track DRAGARWQ market capitalization to gauge the company's total market size. Use the Dr. Agrawals Eye Hospital stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Dr. Agrawals Eye Hospital opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹504 and net income of ₹76, with EBITDA of ₹158, an operating margin of 31.0% and a profit margin of 15.1%.

Dr. Agrawals Eye Hospital Market Cap ₹2,926.28 Cr.
DRAGARWQ P/E Ratio (TTM) 38.70
Dr. Agrawals Eye Hospital P/B Ratio 8.51
EPS (TTM) ₹147.02
Dividend Yield 0.11%
Debt to Equity 1.19
DRAGARWQ 52 Week High ₹6087.50
Dr. Agrawals Eye Hospital 52 Week Low ₹4787.85
Operating Margin 31.00%
Profit Margin 15.08%
DRAGARWQ Revenue (TTM) ₹504.00
EBITDA ₹158.00
Net Income ₹76.00
Total Assets ₹767.00
Total Equity ₹346.00

Dr. Agrawals Eye Hospital Share Price Chart

Track the current stock price of Dr. Agrawals Eye Hospital with an interactive chart. Analyse DRAGARWQ share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Dr. Agrawals Eye Hospital stock quote in one place.

The quote of ₹5,995.50 sits between the 52-week low of ₹4,787.85 and the 52-week high of ₹6,087.50, and the latest session moved -1.51% from the previous close.

Dr. Agrawals Eye Hospital Company Profile - Fundamental Screener

Screen Dr. Agrawals Eye Hospital company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for DRAGARWQ shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Healthcare Services industry, and it trades under ISIN INE934C01018.

Company Details

Classification

Sector Healthcare
Industry Healthcare Services
Sub-Sector Healthcare Services
Segment E

Identifiers and Leadership

ISIN INE934C01018

Dr. Agrawals Eye Hospital Balance Sheet Screener

Screen DRAGARWQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹767, up from ₹613 in 2025.

Latest statistics put total assets at ₹767 and shareholder funds at ₹346, with a leverage ratio of 1.19.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 767 613 496 390 314 155 141 100 81 72
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 403 393 316 260 214 96 94 55 36 33

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 309 317 258 222 183 52 45 19 9 16
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 346 210 157 113 78 55 56 46 35 29
Share Capital 5 5 5 5 5 5 5 5 5 5
Reserves & Surplus 342 205 152 109 74 50 51 41 30 25

Dr. Agrawals Eye Hospital Income Statement Screener - Profit & Revenue Analysis

Screen Dr. Agrawals Eye Hospital income statement and profit fundamentals. Analyze DRAGARWQ quarterly results. Dr. Agrawals Eye Hospital reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹504 and net profit was ₹76, equal to earnings per unit of ₹158.80, at an operating margin of 31%.

In that period expenses were ₹345, interest cost ₹11 and tax ₹25. The next period listed, 2026-March, shows revenue of ₹477 and net profit of ₹70.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 504 477 402 324 270 203 141 179 172 156 150 137 118
Expenses 345 326 279 228 193 144 109 130 141 130 127 120 104

Operating Costs and Margins

EBITDA 158 151 124 96 77 59 31 49 31 26 23 17 15
Operating Profit % 31.00% 31.00% 30.00% 29.00% 28.00% 29.00% 22.00% 26.00% 17.00% 15.00% 14.00% 12.00% 12.00%
Depreciation 47 46 40 27 20 20 19 21 11 10 9 9 6
Interest 11 12 13 7 7 6 6 8 3 3 3 4 3

Profit and Earnings

Profit Before Tax 102 94 71 62 49 32 6 20 17 13 11 -1 5
Tax 25 24 16 16 13 8 7 6 6 7 4 -1 0
Net Profit 76 70 55 46 37 24 -1 14 12 7 7 0 6
EPS 158.80 147.02 116.28 98.64 78.55 51.28 -3.06 29.11 25.35 14.42 15.61 0.08 12.12

Dr. Agrawals Eye Hospital Cash Flow Screener - Liquidity Fundamentals

Screen DRAGARWQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹145, and net cash flow was an outflow of ₹4.

Over the same period, investing activities used ₹174 and financing activities provided ₹25.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 145 94 90 70 57 34 39 25 19 20
Investing Activities -174 -133 -70 -71 -46 -11 -17 -25 -11 -8

Financing and Net Cash

Financing Activities 25 17 -14 0 -4 -8 -20 2 -8 -12
Net Cash Flow -4 -23 6 -1 7 15 2 2 -1 0

Dr. Agrawals Eye Hospital Shareholding Pattern Screener

See Dr. Agrawals Eye Hospital shareholding pattern with promoter, FII, and DII holdings. Check Dr. Agrawals Eye Hospital promoter holding and ownership changes for DRAGARWQ on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 72.67%, foreign institutions 2.20%, domestic institutions 2.12% and the public 17.93%, spread across 24,036 shareholders.

The shareholder count was 24,036 in 2026-Mar, compared with 22,954 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 72.67% 72.67% 72.67% 71.90% 71.90% 72.67% 72.67% 71.90%

Institutional Investors

FII Holding 2.20% 2.24% 2.22% 1.33% 1.50% 1.74% 1.82% 0.64%
DII Holding 2.12% 2.05% 2.54% 1.95% 2.31% 2.36% 2.36% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 17.93% 18.01% 17.58% 19.25% 18.95% 18.17% 17.96% 21.74%
Other Holding 5.07% 5.03% 4.99% 5.57% 5.34% 5.06% 5.19% 5.72%
Shareholder Count 24,036 22,954 21,392 41,704 35,976 30,528 25,449 3,572

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Dr. Agrawals Eye Hospital. Dr. Agrawals Eye Hospital dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹7.00 per unit for 2026-March, a yield of 0.11%, compared with ₹6.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹7.00, ₹6.00 and ₹2.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹7.00 0.11%
2025-March ₹6.00 0.13%
2024-March ₹2.50 0.06%
2023-March ₹3.00 0.10%
2022-March ₹3.00 0.33%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹1.50 0.79%
2018-March ₹1.20 0.33%
2017-March ₹1.50 0.25%

Dr. Agrawals Eye Hospital Stock Index Membership - Nifty & Sensex

See which indices include Dr. Agrawals Eye Hospital stock. Check DRAGARWQ index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Dr. Agrawals Eye Hospital is not part of any tracked indices.
Only major market indices are tracked in our system.

Dr. Agrawals Eye Hospital Market Events Screener - Corporate Actions

Get Dr. Agrawals Eye Hospital corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Dr. Agrawals Eye Hospital stock events that may affect DRAGARWQ share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Merger - Demerger dated November 18, 2026, with a record date of November 18, 2026.

It is followed by Annual General Meeting dated September 9, 2026 and Dividend dated September 2, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-18 2026-11-18 Merger - Demerger 2:23 0.00%
2026-09-09 2026-09-09 Annual General Meeting NA -2.97%
2026-09-02 2026-09-02 Dividend ₹ 4.00 /share 3.68%
2026-08-03 2026-08-03 Quarterly Result Announcement NA -0.38%
2026-07-02 2026-07-02 Extraordinary General Meeting NA 1.66%
2026-05-20 2026-05-20 Quarterly Result Announcement NA 0.41%
2026-02-03 2026-02-03 Quarterly Result Announcement NA -0.08%
2025-11-07 2025-11-07 Dividend ₹ 3.00 /share 2.42%
2025-10-30 2025-10-30 Quarterly Result Announcement NA -3.36%
2025-09-24 2025-09-24 Annual General Meeting NA -7.76%
2025-09-18 2025-09-18 Dividend ₹ 3.50 /share 6.35%
2025-08-12 2025-08-12 Quarterly Result Announcement NA 0.71%
2025-05-28 2025-05-28 Quarterly Result Announcement NA 2.34%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -4.87%
2024-11-08 2024-11-08 Dividend ₹ 2.50 /share 0.26%

Dr. Agrawals Eye Hospital Competitors Screener - Peer Stocks Comparison

Screen DRAGARWQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Apollo Hospitals 124,539 52.40 25,420 15.58% 2,003 57.80
Max Healthcare Institute 96,333 66.60 8,536 18.82% 1,442 62.55
Manipal Health Enterprises 87,479 98.70 10,521 25.80% 917 55.29
Aster DM Quality Care 64,417 111.60 4,769 11.25% 427 54.92
Fortis Healthcare 59,487 54.40 9,179 16.93% 1,064 46.04
Global Health 39,134 63.80 4,509 19.56% 554 68.03
Narayana Hrudayalaya 38,336 44.30 7,996 43.43% 811 56.24
Dr. Lal Path Labs 33,842 56.90 2,864 12.11% 510 56.83
Krishna Institute of Medical Sciences 31,116 155.60 3,931 28.16% 242 54.48
Syngene International 17,788 96.50 3,809 2.56% 317 68.00

Dr. Agrawals Eye Hospital Company Announcements - News & Reports Screener

Screen DRAGARWQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 27, 2026.

The next most recent announcements are dated October 20, 2026 and October 20, 2026.

Date Update Actions
2026-10-27 Disclosure Under Regulation 30 Read With Schedule III Of The Securities And Exchange Board Of India (LODR) Regulations 2015 - Communication To Equity Shareholders -
2026-10-20 Fixation Of Record Date With Respect To The Scheme Of Amalgamation Between Dr. Agarwals Eye Hospital Limited And Dr. Agarwals Health Care Limited -
2026-10-20 Board Meeting Outcome for Material Update On The Scheme Of Amalgamation Between Dr. Agarwals Eye Hospital Limited And Dr. Agarwals Health Care Limited And Their Respective Shareholders And Creditors -
2026-10-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-05 Announcement under Regulation 30 (LODR)-Scheme of Arrangement -
2026-09-28 Closure of Trading Window -
2026-09-10 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-09 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-27 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-08-15 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 32Nd Annual General Meeting Of The Members Of The Company- September 09 2026 -
2026-08-14 Intimation Of Record Date Under Regulation 42 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-08-14 Reg. 34 (1) Annual Report. -
2026-08-14 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -
2026-08-03 Announcement under Regulation 30 (LODR)-Change in Management -
2026-08-03 Results- Unaudited Financial Results For The Quarter Ended June 30 2026 -
2026-08-03 Board Meeting Outcome for Outcome Of The Board Meeting Held On August 03 2026 -
2026-07-28 Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter Ended June 30 2026 -
2026-07-20 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹5,995.50, within a 52-week range of ₹4,787.85 to ₹6,087.50. The P/E ratio is 38.70 and the P/B ratio is 8.51, with earnings per unit of ₹147.02. Market capitalisation stands at ₹2,926.28 Cr and the dividend yield is 0.11%. The company operates in the Healthcare sector, in the Healthcare Services industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.